Benjamin B Kasten1, Ke Jiang2, Denzel Cole3, Aditi Jani4, Neha Udayakumar4, G Yancey Gillespie1, Guolan Lu5, Tingting Dai2, Eben L Rosenthal5, James M Markert1, Jianghong Rao6, Jason M Warram7. 1. Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. 2. Departments of Radiology and Chemistry, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, 94305, USA. 3. Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. 4. School of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. 5. Department of Otolaryngology - Head and Neck Surgery, Stanford University, Stanford, CA, 94305, USA. 6. Departments of Radiology and Chemistry, Molecular Imaging Program at Stanford, Stanford University School of Medicine, Stanford, CA, 94305, USA. jrao@stanford.edu. 7. Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. mojack@uab.edu.
Abstract
PURPOSE: There is a clinical need for agents that target glioma cells for non-invasive and intraoperative imaging to guide therapeutic intervention and improve the prognosis of glioma. Matrix metalloproteinase (MMP)-14 is overexpressed in glioma with negligible expression in normal brain, presenting MMP-14 as an attractive biomarker for imaging glioma. In this study, we designed a peptide probe containing a near-infrared fluorescence (NIRF) dye/quencher pair, a positron emission tomography (PET) radionuclide, and a moiety with high affinity to MMP-14. This novel substrate-binding peptide allows dual modality imaging of glioma only after cleavage by MMP-14 to activate the quenched NIRF signal, enhancing probe specificity and imaging contrast. METHODS: MMP-14 expression and activity in human glioma tissues and cells were measured in vitro by immunofluorescence and gel zymography. Cleavage of the novel substrate and substrate-binding peptides by glioma cells in vitro and glioma xenograft tumors in vivo was determined by NIRF imaging. Biodistribution of the radiolabeled MMP-14-binding peptide or substrate-binding peptide was determined in mice bearing orthotopic patient-derived xenograft (PDX) glioma tumors by PET imaging. RESULTS: Glioma cells with MMP-14 activity showed activation and retention of NIRF signal from the cleaved peptides. Resected mouse brains with PDX glioma tumors showed tumor-to-background NIRF ratios of 7.6-11.1 at 4 h after i.v. injection of the peptides. PET/CT images showed localization of activity in orthotopic PDX tumors after i.v. injection of 68Ga-binding peptide or 64Cu-substrate-binding peptide; uptake of the radiolabeled peptides in tumors was significantly reduced (p < 0.05) by blocking with the non-labeled-binding peptide. PET and NIRF signals correlated linearly in the orthotopic PDX tumors. Immunohistochemistry showed co-localization of MMP-14 expression and NIRF signal in the resected tumors. CONCLUSIONS: The novel MMP-14 substrate-binding peptide enabled PET/NIRF imaging of glioma models in mice, warranting future image-guided resection studies with the probe in preclinical glioma models.
PURPOSE: There is a clinical need for agents that target glioma cells for non-invasive and intraoperative imaging to guide therapeutic intervention and improve the prognosis of glioma. Matrix metalloproteinase (MMP)-14 is overexpressed in glioma with negligible expression in normal brain, presenting MMP-14 as an attractive biomarker for imaging glioma. In this study, we designed a peptide probe containing a near-infrared fluorescence (NIRF) dye/quencher pair, a positron emission tomography (PET) radionuclide, and a moiety with high affinity to MMP-14. This novel substrate-binding peptide allows dual modality imaging of glioma only after cleavage by MMP-14 to activate the quenched NIRF signal, enhancing probe specificity and imaging contrast. METHODS:MMP-14 expression and activity in humanglioma tissues and cells were measured in vitro by immunofluorescence and gel zymography. Cleavage of the novel substrate and substrate-binding peptides by glioma cells in vitro and glioma xenograft tumors in vivo was determined by NIRF imaging. Biodistribution of the radiolabeled MMP-14-binding peptide or substrate-binding peptide was determined in mice bearing orthotopic patient-derived xenograft (PDX) glioma tumors by PET imaging. RESULTS:Glioma cells with MMP-14 activity showed activation and retention of NIRF signal from the cleaved peptides. Resected mouse brains with PDX glioma tumors showed tumor-to-background NIRF ratios of 7.6-11.1 at 4 h after i.v. injection of the peptides. PET/CT images showed localization of activity in orthotopic PDX tumors after i.v. injection of 68Ga-binding peptide or 64Cu-substrate-binding peptide; uptake of the radiolabeled peptides in tumors was significantly reduced (p < 0.05) by blocking with the non-labeled-binding peptide. PET and NIRF signals correlated linearly in the orthotopic PDX tumors. Immunohistochemistry showed co-localization of MMP-14 expression and NIRF signal in the resected tumors. CONCLUSIONS: The novel MMP-14 substrate-binding peptide enabled PET/NIRF imaging of glioma models in mice, warranting future image-guided resection studies with the probe in preclinical glioma models.
Entities:
Keywords:
Dual modality; Glioma; MMP-14; Molecular imaging; NIRF; PET
Authors: Marc D Piroth; Richard Holy; Michael Pinkawa; Gabriele Stoffels; Hans J Kaiser; Norbert Galldiks; Hans Herzog; Heinz H Coenen; Michael J Eble; Karl J Langen Journal: Radiother Oncol Date: 2011-04-16 Impact factor: 6.280
Authors: Jonathan T Elliott; Kayla Marra; Linton T Evans; Scott C Davis; Kimberley S Samkoe; Joachim Feldwisch; Keith D Paulsen; David W Roberts; Brian W Pogue Journal: Clin Cancer Res Date: 2016-10-31 Impact factor: 12.531
Authors: Bogdana Suchorska; Nathalie L Jansen; Jennifer Linn; Hans Kretzschmar; Hendrik Janssen; Sabina Eigenbrod; Matthias Simon; Gabriele Pöpperl; Friedrich W Kreth; Christian la Fougere; Michael Weller; Joerg C Tonn Journal: Neurology Date: 2015-01-21 Impact factor: 9.910
Authors: Christian P Filss; Norbert Galldiks; Gabriele Stoffels; Michael Sabel; Hans J Wittsack; Bernd Turowski; Gerald Antoch; Ke Zhang; Gereon R Fink; Heinz H Coenen; Nadim J Shah; Hans Herzog; Karl-Josef Langen Journal: J Nucl Med Date: 2014-02-27 Impact factor: 10.057
Authors: Georgina Gonzalez-Avila; Bettina Sommer; A Armando García-Hernandez; Carlos Ramos; Edgar Flores-Soto Journal: Front Mol Biosci Date: 2022-06-01
Authors: Syed Muhammad Usama; Sierra C Marker; Servando Hernandez Vargas; Solmaz AghaAmiri; Sukhen C Ghosh; Naruhiko Ikoma; Hop S Tran Cao; Martin J Schnermann; Ali Azhdarinia Journal: Cancers (Basel) Date: 2022-03-23 Impact factor: 6.639
Authors: Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco Journal: Int J Mol Sci Date: 2020-08-06 Impact factor: 5.923